Ex vivo gene therapy to produce bone using different cell types

Douglas S. Musgrave, Patrick Bosch, Joon Y. Lee, Dalip Pelinkovic, Steve C. Ghivizzani, Janey Whalen, Christopher Niyibizi, Johnny Huard

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Gene therapy and tissue engineering promise to revolutionize orthopaedic surgery. This study comprehensively compares five different cell types in ex vivo gene therapy to produce bone. The cell types include a bone marrow stromal cell line, primary muscle derived cells, primary bone marrow stromal cells, primary articular chondrocytes, and primary fibroblasts. After transduction by an adenovirus encoding for bone morphogenetic protein-2, all of the cell types were capable of secreting bone morphogenetic protein-2. However, the bone marrow stromal cell line and muscle derived cells showed more responsiveness to recombinant human bone morphogenetic protein-2 than did the other cell types. In vivo injection of each of the cell populations transduced to secrete bone morphogenetic protein-2 resulted in bone formation. Radiographic and histologic analyses corroborated the in vitro data regarding bone morphogenetic protein-2 secretion and cellular osteocompetence. This study showed the feasibility of using primary bone marrow stromal cells, primary muscle derived cells, primary articular chondrocytes, primary fibroblasts, and an osteogenesis imperfecta stromal cell line in ex vivo gene therapy to produce bone. The study also showed the advantages and disadvantages inherent in using each cell type.

Original languageEnglish (US)
Pages (from-to)290-305
Number of pages16
JournalClinical orthopaedics and related research
Issue number378
DOIs
StatePublished - Jan 1 2000

Fingerprint

Genetic Therapy
Bone Morphogenetic Protein 2
Mesenchymal Stromal Cells
Bone and Bones
Muscle Cells
Chondrocytes
Cell Line
Fibroblasts
Joints
Osteogenesis Imperfecta
Feasibility Studies
Tissue Engineering
Stromal Cells
Adenoviridae
Osteogenesis
Orthopedics
Injections
Population

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Musgrave, D. S., Bosch, P., Lee, J. Y., Pelinkovic, D., Ghivizzani, S. C., Whalen, J., ... Huard, J. (2000). Ex vivo gene therapy to produce bone using different cell types. Clinical orthopaedics and related research, (378), 290-305. https://doi.org/10.1097/00003086-200009000-00040
Musgrave, Douglas S. ; Bosch, Patrick ; Lee, Joon Y. ; Pelinkovic, Dalip ; Ghivizzani, Steve C. ; Whalen, Janey ; Niyibizi, Christopher ; Huard, Johnny. / Ex vivo gene therapy to produce bone using different cell types. In: Clinical orthopaedics and related research. 2000 ; No. 378. pp. 290-305.
@article{e5bf1397f82b4696bbae0fd07ad38cdc,
title = "Ex vivo gene therapy to produce bone using different cell types",
abstract = "Gene therapy and tissue engineering promise to revolutionize orthopaedic surgery. This study comprehensively compares five different cell types in ex vivo gene therapy to produce bone. The cell types include a bone marrow stromal cell line, primary muscle derived cells, primary bone marrow stromal cells, primary articular chondrocytes, and primary fibroblasts. After transduction by an adenovirus encoding for bone morphogenetic protein-2, all of the cell types were capable of secreting bone morphogenetic protein-2. However, the bone marrow stromal cell line and muscle derived cells showed more responsiveness to recombinant human bone morphogenetic protein-2 than did the other cell types. In vivo injection of each of the cell populations transduced to secrete bone morphogenetic protein-2 resulted in bone formation. Radiographic and histologic analyses corroborated the in vitro data regarding bone morphogenetic protein-2 secretion and cellular osteocompetence. This study showed the feasibility of using primary bone marrow stromal cells, primary muscle derived cells, primary articular chondrocytes, primary fibroblasts, and an osteogenesis imperfecta stromal cell line in ex vivo gene therapy to produce bone. The study also showed the advantages and disadvantages inherent in using each cell type.",
author = "Musgrave, {Douglas S.} and Patrick Bosch and Lee, {Joon Y.} and Dalip Pelinkovic and Ghivizzani, {Steve C.} and Janey Whalen and Christopher Niyibizi and Johnny Huard",
year = "2000",
month = "1",
day = "1",
doi = "10.1097/00003086-200009000-00040",
language = "English (US)",
pages = "290--305",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "378",

}

Musgrave, DS, Bosch, P, Lee, JY, Pelinkovic, D, Ghivizzani, SC, Whalen, J, Niyibizi, C & Huard, J 2000, 'Ex vivo gene therapy to produce bone using different cell types', Clinical orthopaedics and related research, no. 378, pp. 290-305. https://doi.org/10.1097/00003086-200009000-00040

Ex vivo gene therapy to produce bone using different cell types. / Musgrave, Douglas S.; Bosch, Patrick; Lee, Joon Y.; Pelinkovic, Dalip; Ghivizzani, Steve C.; Whalen, Janey; Niyibizi, Christopher; Huard, Johnny.

In: Clinical orthopaedics and related research, No. 378, 01.01.2000, p. 290-305.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ex vivo gene therapy to produce bone using different cell types

AU - Musgrave, Douglas S.

AU - Bosch, Patrick

AU - Lee, Joon Y.

AU - Pelinkovic, Dalip

AU - Ghivizzani, Steve C.

AU - Whalen, Janey

AU - Niyibizi, Christopher

AU - Huard, Johnny

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Gene therapy and tissue engineering promise to revolutionize orthopaedic surgery. This study comprehensively compares five different cell types in ex vivo gene therapy to produce bone. The cell types include a bone marrow stromal cell line, primary muscle derived cells, primary bone marrow stromal cells, primary articular chondrocytes, and primary fibroblasts. After transduction by an adenovirus encoding for bone morphogenetic protein-2, all of the cell types were capable of secreting bone morphogenetic protein-2. However, the bone marrow stromal cell line and muscle derived cells showed more responsiveness to recombinant human bone morphogenetic protein-2 than did the other cell types. In vivo injection of each of the cell populations transduced to secrete bone morphogenetic protein-2 resulted in bone formation. Radiographic and histologic analyses corroborated the in vitro data regarding bone morphogenetic protein-2 secretion and cellular osteocompetence. This study showed the feasibility of using primary bone marrow stromal cells, primary muscle derived cells, primary articular chondrocytes, primary fibroblasts, and an osteogenesis imperfecta stromal cell line in ex vivo gene therapy to produce bone. The study also showed the advantages and disadvantages inherent in using each cell type.

AB - Gene therapy and tissue engineering promise to revolutionize orthopaedic surgery. This study comprehensively compares five different cell types in ex vivo gene therapy to produce bone. The cell types include a bone marrow stromal cell line, primary muscle derived cells, primary bone marrow stromal cells, primary articular chondrocytes, and primary fibroblasts. After transduction by an adenovirus encoding for bone morphogenetic protein-2, all of the cell types were capable of secreting bone morphogenetic protein-2. However, the bone marrow stromal cell line and muscle derived cells showed more responsiveness to recombinant human bone morphogenetic protein-2 than did the other cell types. In vivo injection of each of the cell populations transduced to secrete bone morphogenetic protein-2 resulted in bone formation. Radiographic and histologic analyses corroborated the in vitro data regarding bone morphogenetic protein-2 secretion and cellular osteocompetence. This study showed the feasibility of using primary bone marrow stromal cells, primary muscle derived cells, primary articular chondrocytes, primary fibroblasts, and an osteogenesis imperfecta stromal cell line in ex vivo gene therapy to produce bone. The study also showed the advantages and disadvantages inherent in using each cell type.

UR - http://www.scopus.com/inward/record.url?scp=0033852160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033852160&partnerID=8YFLogxK

U2 - 10.1097/00003086-200009000-00040

DO - 10.1097/00003086-200009000-00040

M3 - Article

C2 - 10987005

AN - SCOPUS:0033852160

SP - 290

EP - 305

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 378

ER -

Musgrave DS, Bosch P, Lee JY, Pelinkovic D, Ghivizzani SC, Whalen J et al. Ex vivo gene therapy to produce bone using different cell types. Clinical orthopaedics and related research. 2000 Jan 1;(378):290-305. https://doi.org/10.1097/00003086-200009000-00040